Severe neutropenia remains the main cause of morbidity and mortality after autologous stem cell transplantation (ASCT). Improvements in this procedure, such as the use of peripheral blood progenitor cells and the administration of an oral antibiotic prophylaxis, have reduced the incidence of infections during the time of neutropenia and have made ASCT safer. [1] [2] [3] The use of G-CSF after ASCT with the intention of reducing the duration of neutropenia and minimising the risk of severe infection is a common practice in most transplantation centres. In addition, because of a faster neutrophil recovery, G-CSF administration may also be associated with a reduction in the incidence and severity of oral and intestinal mucositis after ASCT. 4 However, it has been reported that G-CSF administration after ASCT does not reduce the incidence or duration of febrile neutropenia or the infectious mortality rate. [5] [6] [7] [8] Moreover, G-CSF administration has been associated with a higher incidence of clinical complications such as engraftment syndrome (ES) and capillary leak syndrome. [9] [10] [11] For these reasons, its use after ASCT is controversial. 11, 12 Thus, in May 2011, our centre discontinued the administration of post-transplant G-CSF in patients with multiple myeloma (MM). We hypothesised that the use of G-CSF in these patients does not provide any significant clinical benefit as compared with not using G-CSF. Here we report the results of this policy by comparing two cohorts of patients; one cohort received post-transplant G-CSF, whereas the other cohort did not receive G-CSF.
One hundred ninety-five patients with MM underwent an ASCT between November 2000 and October 2014. Of them, 131 (67%) were not included in an at-home ASCT programme because of ECOG 42 (35%), patient decision (27%), geographic distance (21%) and no caregiver available (17%). Finally, 64 (33%) patients were included. The hospital ethics committee approved this programme and all patients signed a written informed consent.
Patient-, disease-and transplant-related variables are described in Table 1 . All patients received high-dose melphalan (200 mg/m 2 ) and a peripheral blood stem cell infusion in the hospital and were discharged on day +1.
Specialised nurses in Hematology looked after the patients daily, either at home or by phone. They checked patients' vital signs, oral intake, central venous catheter status and presence of mucositis; they administered IV medications and they took blood samples. If necessary, medical assistance was provided in the hospital by a designated physician or by the haematologist on call. 
4) NS
Abbreviations: CR = complete response; G-CSF = granulocyte colony-stimulating factor; MR = minimal response; NS = no significant; PR = partial response; VGPR = very good partial response.
Neutrophil engraftment was defined as the first of two consecutive days of an ANC of 40.5 × 10 9 /L, and platelet engraftment as the first of two consecutive days with a platelet count 420 × 10 9 /L without transfusion support. Febrile neutropenia was defined as a temperature of ⩾ 38°C in a patient with o 0.5 × 10 9 /L neutrophils. ES was defined following Maiolino's criteria. 9 Patients with suspected ES received corticosteroids at a dose of 1 mg/kg twice daily for 3 days and then tapered over 7-8 days. Mucositis and intestinal toxicity were defined following the World Health Organization (WHO) scale.
Criteria for hospital admission included patient or caregiver consent, hemodynamic instability, cardiac and/or respiratory distress, and any other WHO grade 3 or 4 side effect. Discharge criteria included an ANC 41 × 10 9 /L with all possible complications solved.
Characteristics between the groups were compared using χ 2 -test or Fisher's exact test (two-tailed) and T -test or the Mann-Whitney U. The level of significance was set at P o0.05. All analyses were carried out using SPSS version 21 statistical software (SPSS Inc., Chicago, IL, USA). Results are shown in Table 2 . The median days of G-CSF administration in the G-CSF group was 6 (range 2-30). Neutrophil engraftment was achieved at a median of 12 days (range 10-26) post transplant in patients receiving G-CSF, compared with 14 days (range [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] for the non-G-CSF group (P = 0.01). Similarly, the number of days of neutropenia being ⩽ 0.5 × 10 9 /L was significantly different between the groups with a median of 8 days (range 5-22) in the G-CSF group vs 11 days (range 5-18) in the non-G-CSF group (P = 0.01). No differences were observed in the duration of neutropenia ⩽ 0.1 × 10 9 /L and in the time to platelet engraftment.
No significant differences were observed in the incidence or duration of fever, in the median day of the appearance of fever, in the frequency or type of microbiological isolation, or in the duration of IV antibiotic treatment between the two groups.
No significant differences were observed in the incidence of WHO oral or intestinal toxicity grades 3 and 4 or in the incidence of ES between the groups. The most frequent symptoms of the ES were fever (100%), rash (67%) and diarrhoea (58%). Patients who received G-CSF seemed to have more severe ES. Three patients (43%) with ES from the G-CSF group had to be admitted: one for hypotension, one for respiratory failure and one for persistent high fever. Only one patient (25%) from the non-G-CSF group with ES required hospitalisation, because of hypotension (P = NS).
The median duration of the whole procedure was 2 days shorter in the G-CSF group (14 vs 16 days) (P = NS). Readmission was necessary for seven patients (11%), five (16%) in the G-CSF group and two (6%) in the non-G-CSF group (P = NS). As mentioned above, the reason for readmission in three of the five patients in the G-CSF group was ES. The reason for readmission in the non-G-CSF group was ES in one case and respiratory failure due to syncytial virus pneumonitis in the other case. This second patient died on day +35. The total number of re-hospitalisation days was 62 with a median duration of 4 days (range 4-35).
Outpatient ASCTs are used increasingly in bone marrow transplant centres. One of the most significant limitations of these programmes is the frequent need for hospital admission for fever during the post-transplant neutropenic period, and as such, the prophylaxis for neutropenic fever may differ between outpatients and inpatients. In this sense, our group has shown that febrile neutropenia in an at-home ASCT programme is significantly reduced by adding IV ceftriaxone, which results in a very low readmission rate. 2 In this study, both the lower febrile neutropenia and the successful control of fever at home resulted in an overall readmission rate significantly lower than that observed in previous outpatient ASCT series (11% vs 50-70%, respectively). 3, 8 Prior studies have reported that the use of G-CSF after ASCT accelerates neutrophil recovery by 2-9 days. 6 We have also reproduced these data; however, we did not observe any differences in the incidence and duration of febrile neutropenia, in the incidence of serious infections requiring hospital readmission or in the duration of IV antibiotic therapy, as other authors have found. 7, 8 Oral and intestinal mucositis is a very common and debilitating adverse event. It has a negative impact on patients' quality of life and it can lead to dehydration, malnutrition and serious infections, all of which have a particularly negative impact on at-home ASCT. In a European multi-centre study, the duration of severe oral mucositis was correlated with time to neutrophil engraftment. 13 Following this, we analysed whether eliminating G-CSF post transplant might increase the incidence, duration, or severity of oral and intestinal mucositis. However, the non-G-CSF group did not show a higher incidence of oral or intestinal toxicity. Days of engraftment, first day of fever, duration of fever, duration of IV empirical antibiotic and days to discharge are given in median (range) days.
Finally, several studies have reported that G-CSF may increase the incidence of ES. 10, 11 In our series, there was no difference regardless of whether the patients received G-CSF, although there was a trend towards greater severity of the ES for those who had received G-CSF. It has been reported that the incidence of ES after ASCT for MM is higher for those patients who received bortezomib, as compared with those who received chemotherapy.
14 In this sense, more patients in the non-G-CSF group received bortezomib instead of chemotherapy. Despite that, the non-G-CSF group did not show more ES than the G-CSF group.
The policy of not giving G-CSF in the at-home ASCT setting did not increase the incidence or severity of infections, nor did it impact the severity or duration of mucositis. We did not perform a pharmacoeconomical analysis, but it is very likely that the cost of the at-home ASCT was also reduced, as has been suggested in previous studies. 8, 15 In conclusion, the use of G-CSF in at-home ASCT for patients with MM is not required.
